Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Volume Increase on Analyst Upgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw an uptick in trading volume on Wednesday after DZ Bank upgraded the stock from a hold rating to a strong-buy rating. 5,162,483 shares traded hands during trading, an increase of 301% from the previous session’s volume of 1,287,501 shares.The stock last traded at $11.3648 and had previously closed at $11.05.

Several other research analysts have also commented on BAYRY. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 1.5%

The stock has a fifty day moving average of $11.29 and a 200 day moving average of $11.09. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.63 and a current ratio of 1.01. The company has a market capitalization of $43.66 billion, a PE ratio of -17.36, a PEG ratio of 3.61 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.The company had revenue of $15.73 billion for the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.